alzheon, Author at Alzheon | Preserving Future Memories - Page 13 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 208 blog entries.

18 May, 2019

Alzheon to Make Presentations at Upcoming Industry Conferences May – June

alzheon2024-08-12T09:17:01-04:00May 18th, 2019|

18 Jan, 2019

Alzheon to Make Presentations at Upcoming Industry Conferences January – February

alzheon2024-08-12T09:09:55-04:00January 18th, 2019|

24 Oct, 2018

APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Alzheon to Present Clinical Data at 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

alzheon2024-08-05T14:33:45-04:00October 24th, 2018|

12 Sep, 2018

Alzheon to Make Presentations at Upcoming Industry and Medical Conferences

alzheon2024-08-05T18:07:01-04:00September 12th, 2018|

6 Aug, 2018

Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease

alzheon2024-08-02T11:00:26-04:00August 6th, 2018|

6 Aug, 2018

Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors

alzheon2024-08-05T14:56:26-04:00August 6th, 2018|

3 Aug, 2018

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain

alzheon2024-06-19T16:49:25-04:00August 3rd, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|